Fig. 2From: Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysisNetwork of treatment comparisons for efficacy outcomes. *Numbers inside node represent number of studies, number of patients for each core agentBack to article page